ERBB2 and lung cancer: Lung cancer was detected with 76% sensitivity and 92% specificity when seven autoantibodies (anti-c-Myc, -p53, -HER-2, -Muc-1, -NY-ESO-1, -CAGE and -GBU4-4 IgGs) were combined [73], and primary breast cancer was detected with 64% sensitivity and 85% specificity with a panel of seven autoantibodies (anti-p53, -c-Myc, -HER-2, -NY-ESO-1, -BRCA1, -BRCA2 and -Muc-1 IgGs) [74].